BCAX
NASDAQ · Biotechnology
Bicara Therapeutics Inc
$8.89
-0.07 (-0.78%)
Open$9.19
Previous Close$8.96
Day High$9.28
Day Low$8.69
52W High$30.99
52W Low$8.90
Volume—
Avg Volume2.47M
Market Cap604.16M
P/E Ratio—
EPS$-3.09
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
+63.1% upside
Current
$8.89
$8.89
Target
$14.50
$14.50
$9.75
$14.50 avg
$19.19
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 181.36M | 184.14M | 159.71M |
| Net Income | -39,755,825 | -41,476,631 | -32,201,263 |
| Profit Margin | -21.9% | -22.5% | -20.2% |
| EBITDA | -52,674,751 | -54,395,580 | -46,526,832 |
| Free Cash Flow | -41,149,249 | -44,589,211 | -37,987,097 |
| Rev Growth | +5.9% | -5.2% | -5.4% |
| Debt/Equity | 0.58 | 0.56 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |